Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AIMT

Aimmune Therapeutics (AIMT) Stock Price, News & Analysis

Aimmune Therapeutics logo

About Aimmune Therapeutics Stock (NASDAQ:AIMT)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$34.49
$34.49
50-Day Range
$34.30
$34.59
52-Week Range
$10.09
$37.00
Volume
N/A
Average Volume
1.71 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Remove Ads
Receive AIMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AIMT Stock News Headlines

Aimtron Electronics Ltd (AIMT)
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Headlines

AIMT Stock Analysis - Frequently Asked Questions

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) issued its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($1.06).

Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Meta Platforms (META), Xtrackers California Municipal Bond ETF (CA) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
7/30/2020
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AIMT
Fax
N/A
Employees
228
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-248,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.66 per share
Price / Book
20.78

Miscellaneous

Free Float
N/A
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.76
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:AIMT) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners